Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,725,755	$ 16,612,315
Research and development tax incentive receivable	361,485	186,507
Prepaid assets and other current assets	805,659	2,226,344
Total current assets	10,892,899	19,025,166
Operating lease right-of-use asset, net	139,230	196,044
Property and equipment, net	2,064,354	3,078,342
Note receivable - Augmenta	1,781,000	1,812,975
Other assets	7,688	7,688
Total assets	14,885,171	24,120,215
Current liabilities:
Accounts payable	983,287	919,607
Accrued compensation		4,430
Deferred research grant revenue	76,000	126,000
Current portion of operating lease liability	82,725	80,625
Total current liabilities	1,142,012	1,130,662
Operating lease liability, net of current portion	52,230	110,094
Total liabilities	1,194,242	1,240,756
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 90,000,000 shares and 45,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; 59,133,574 and 36,193,085 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	59,134	36,193
Additional paid-in capital	127,404,746	120,070,983
Accumulated other comprehensive loss	(203,712)	(139,295)
Accumulated deficit	(113,569,239)	(97,088,422)
Total stockholders’ equity	13,690,929	22,879,459
Total liabilities and stockholders’ equity	$ 14,885,171	$ 24,120,215